NASDAQ · SERA
Sera Prognostics, Inc.
Healthcare · Medical - Diagnostics & Research
$2.11▲ 2.43% ($0.05)at close
As of 4:00 PM ET
Market cap
$80.58M
P/E
-3.15
EPS (TTM)
-$0.66
Next earnings
Nov 12, 2026
Valuation
Revenue & margin DCF
Verdict: expensive. Price above all scenarios.
The price needs 34.0% revenue growth a year for 10 years. Our scenarios assume 12.4–21.5%.
Its past 4 years averaged −0.3% a year.
Value per share
Base case
$1.22
Price used $2.11 is 1.7× this
USD · TTM ending Jun 30, 2026 · Price Sep 24, 8:00 PM UTC
Reported operating earnings and the comparable cash-flow estimate differ substantially; the model retains the reported-margin anchor.
Revenue each value needs
Revenue today $70K. The price needs $1.3M by 2036. Base case: $344K. At its recent pace: $67.9K. Bear to Bull: $226K to $493K.
Revenue today $70K. The price needs $1.3M by 2036. Base case: $344K. At its recent pace: $67.9K. Bear to Bull: $226K to $493K.
Revenue in 2036
today $70K
+$967Kmore than the Base case · 3.8×
Value per share · Base case
$1.22
Price $2.11
1.7× this
- 10-yr revenue CAGR
- 17.3%
- Ending operating margin
- 0.0%
- Discount rate
- 10.6%
Reported operating earnings and the comparable cash-flow estimate differ substantially; the model retains the reported-margin anchor.
USD · TTM ending Jun 30, 2026 · Price Sep 24, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 31.72% over the last year. Revenue declined 35.19% over the trailing twelve months. Operating margin moved from -34,125% to -53,282.86%. Free cash flow declined 4.46% over the trailing twelve months.
What the market seems to be pricing
The market appears to be responding to weaker operating momentum rather than only rerating the stock.
What would invalidate this read
Operating margin stands at -53,282.86%. Revenue declined 35.19% — this read reverses if that trend stabilizes. Free cash flow fell 4.46% — a return toward positive territory would undermine the deterioration thesis. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.
Return analysis
Company profile
Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results.
Market multiples
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
4
Buy
1
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 12, 2026
Q4 FY26 · EPS est -$0.14 · Revenue est $75K
View
Institutional Sentiment
Sera Prognostics, Inc. · SERA
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.